Targeted Oncology

, Volume 10, Issue 3, pp 405–413 | Cite as

Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack

  • Marc Cinci
  • Srinivas Mamidi
  • Wenhan Li
  • Volker Fehring
  • Michael Kirschfink
Original Research

Abstract

The overexpression of membrane-bound complement regulatory proteins (mCRP; CD46, CD55, CD59) preventing opsonization and complement-dependent cytotoxicity (CDC) is considered a major barrier for successful antibody-based cancer immunotherapy. To avoid a potential deleterious effect of mCRP neutralization on normal tissue cells, complement regulation has to be selectively targeted to the malignant cells. In this study, anti-mCRP small interfering RNAs (siRNAs) were encapsulated in transferrin-coupled lipoplexes for the specific delivery to transferrin receptor CD71high expressing BT474, DU145, and SW480 as well as corresponding CD71-knockdown (CD71low) tumor cells. Targeted delivery with transferrin-siRNA-lipoplexes became possible by charge neutralization and resulted in efficient silencing of all three mCRPs up to 90 %, which is dependent on their CD71 expression. The mCRP knockdown led to a significant increase of CDC on CD71high tumor cells by 68 % in BT474, 58 % in DU145, and 40 % in SW480 cells but only slightly increased on CD71low cells. Downregulation of CD46 and CD55 significantly increased C3 opsonization only on CD71high tumor cells. Our results demonstrate for the first time that by specific delivery of anti-mCRP siRNA through transferrin receptor, complement regulation can be selectively neutralized, allowing specific antibody-mediated killing of tumor cells without affecting healthy bystander cells, which appears to be a suited strategy to improve antibody-based cancer immunotherapy.

Keywords

Complement-dependent cytotoxicity Immunotherapy Membrane complement regulatory proteins siRNA Transferrin receptor Tumor cell targeting 

Notes

Acknowledgments

The study was supported by the “BMBF BIODISC (0315503)” and the “Exzellenzinitiative, Innovationfonds Frontier Programme, University of Heidelberg,” and by the “Stiftung für Krebs–und Scharlachforschung Mannheim”.

Conflict of interest

The authors disclose no potential conflicts of interest.

References

  1. 1.
    Carroll MC (2004) The complement system in regulation of adaptive immunity. Nat Immunol 5:981–986CrossRefPubMedGoogle Scholar
  2. 2.
    Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058–1066CrossRefPubMedGoogle Scholar
  3. 3.
    Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11:785–797PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Gasque P, Morgan BP, Legoedec J, Chan P, Fontaine M (1996) Human skeletal myoblasts spontaneously activate allogeneic complement but are resistant to killing. J Immunol 156:3402–3411PubMedGoogle Scholar
  5. 5.
    Goldberger G, Arnaout MA, Aden D, Kay R, Rits M, Colten HR (1984) Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines. J Biol Chem 259:6492–6497PubMedGoogle Scholar
  6. 6.
    Jurianz K, Ziegler S, Donin N, Reiter Y, Fishelson Z, Kirschfink M (2001) K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int J Cancer J Int du Cancer 93:848–854CrossRefGoogle Scholar
  7. 7.
    Li L, Spendlove I, Morgan J, Durrant LG (2001) CD55 is over-expressed in the tumour environment. Br J Cancer 84:80–86PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Thomas A, Gasque P, Vaudry D, Gonzalez B, Fontaine M (2000) Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol 12:1015–1023CrossRefPubMedGoogle Scholar
  9. 9.
    Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z (2003) Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 131:254–263PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Frade R (1999) Structure and functions of proteases which cleave human C3 and are expressed on normal or tumor human cells: some are involved in tumorigenic and metastatic properties of human melanoma cells. Immunopharmacology 42:39–45CrossRefPubMedGoogle Scholar
  11. 11.
    Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M (2003) Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40:109–123CrossRefPubMedGoogle Scholar
  12. 12.
    Gorter A, Meri S (1999) Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 20:576–582CrossRefPubMedGoogle Scholar
  13. 13.
    Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ (2008) Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res Off J Am Assoc Cancer Res 14:1561–1570CrossRefGoogle Scholar
  14. 14.
    Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, Brown JR, Qin X (2011) rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res Off J Am Assoc Cancer Res 17:6702–6711CrossRefGoogle Scholar
  15. 15.
    Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98:3383–3389CrossRefPubMedGoogle Scholar
  16. 16.
    Macor P, Tripodo C, Zorzet S, Piovan E, Bossi F, Marzari R, Amadori A, Tedesco F (2007) In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 67:10556–10563CrossRefPubMedGoogle Scholar
  17. 17.
    Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S (2006) Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res 30:625–631CrossRefPubMedGoogle Scholar
  18. 18.
    Zhao WP, Zhu B, Duan YZ, Chen ZT (2009) Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells. Oncol Rep 21:1405–1411PubMedGoogle Scholar
  19. 19.
    Hu W, Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA, Brown JR, Qin X (2011) Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res 71:2298–2307PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Geis N, Zell S, Rutz R, Li W, Giese T, Mamidi S, Schultz S, Kirschfink M (2010) Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Curr Cancer Drug Targets 10:922–931CrossRefPubMedGoogle Scholar
  21. 21.
    Mamidi S, Cinci M, Hasmann M, Fehring V, Kirschfink M (2013) Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. Molec Oncol 7:580–594CrossRefGoogle Scholar
  22. 22.
    Zell S, Geis N, Rutz R, Schultz S, Giese T, Kirschfink M (2007) Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin Exp Immunol 150:576–584PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, Clezardin P, Cabon F (2003) SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 63:3919–3922PubMedGoogle Scholar
  24. 24.
    Tolentino MJ, Brucker AJ, Fosnot J, Ying GS, Wu IH, Malik G, Wan S, Reich SJ (2004) Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 24:132–138CrossRefPubMedGoogle Scholar
  25. 25.
    Park JW, Benz CC, Martin FJ (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31:196–205CrossRefPubMedGoogle Scholar
  26. 26.
    Camp ER, Wang C, Little EC, Watson PM, Pirollo KF, Rait A, Cole DJ, Chang EH, Watson DK (2013) Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther 20:222–228PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Cardoso AL, Simoes S, de Almeida LP, Plesnila N, Pedroso de Lima MC, Wagner E, Culmsee C (2008) Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS. J Cont Rel Off J Cont Rel Soc 132:113–123CrossRefGoogle Scholar
  28. 28.
    Dufes C, Al Robaian M, Somani S (2013) Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Ther Deliv 4:629–640CrossRefPubMedGoogle Scholar
  29. 29.
    Li X, Ding L, Xu Y, Wang Y, Ping Q (2009) Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm 373:116–123CrossRefPubMedGoogle Scholar
  30. 30.
    Liu Y, Tao J, Li Y, Yang J, Yu Y, Wang M, Xu X, Huang C, Huang W, Dong J, Li L, Liu J, Shen G, Tu Y (2009) Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth. Molec Ther J Am Soc Gene Ther 17:269–277CrossRefGoogle Scholar
  31. 31.
    Mendonca LS, Firmino F, Moreira JN, Pedroso de Lima MC, Simoes S (2010) Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem 21:157–168CrossRefPubMedGoogle Scholar
  32. 32.
    Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, Dames S, Loffler K, Fechtner M, Arnold W, Giese K, Klippel A, Kaufmann J (2006) A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 13:1222–1234CrossRefPubMedGoogle Scholar
  33. 33.
    Jurianz K, Maslak S, Garcia-Schuler H, Fishelson Z, Kirschfink M (1999) Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology 42:209–218CrossRefPubMedGoogle Scholar
  34. 34.
    Ben-Kasus T, Schechter B, Sela M, Yarden Y (2007) Cancer therapeutic antibodies come of age: targeting minimal residual disease. Molec Oncol 1:42–54CrossRefGoogle Scholar
  35. 35.
    Gancz D, Fishelson Z (2009) Cancer resistance to complement-dependent cytotoxicity (CDC): problem-oriented research and development. Mol Immunol 46:2794–2800CrossRefPubMedGoogle Scholar
  36. 36.
    Horl S, Banki Z, Huber G, Ejaz A, Mullauer B, Willenbacher E, Steurer M, Stoiber H (2013) Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells. Haematologica 98:1939–1947PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Horl S, Banki Z, Huber G, Ejaz A, Windisch D, Muellauer B, Willenbacher E, Steurer M, Stoiber H (2013) Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity. Leukemia 27:2200–2208PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Lindorfer MA, Beum PV, Taylor RP (2013) CD20 mAb-mediated complement dependent cytotoxicity of tumor cells is enhanced by blocking the action of factor I. Antibodies 2:598–616CrossRefGoogle Scholar
  39. 39.
    Czauderna F, Fechtner M, Dames S, Aygun H, Klippel A, Pronk GJ, Giese K, Kaufmann J (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31:2705–2716PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Judge AD, Bola G, Lee AC, MacLachlan I (2006) Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Molec Ther J Am Soc Gene Ther 13:494–505CrossRefGoogle Scholar
  41. 41.
    Carbognani P, Rusca M, Romani A, Spaggiari L, Cattelani L, Solli P, Bobbio P (1996) Transferrin receptor expression in nonsmall cell lung cancer: histopathologic and clinical correlates. Cancer 78:178–179CrossRefPubMedGoogle Scholar
  42. 42.
    Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML (2006) The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121:144–158CrossRefPubMedGoogle Scholar
  43. 43.
    Ryschich E, Huszty G, Knaebel HP, Hartel M, Buchler MW, Schmidt J (2004) Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer 40:1418–1422CrossRefPubMedGoogle Scholar
  44. 44.
    Smilevska T, Stamatopoulos K, Samara M, Belessi C, Tsompanakou A, Paterakis G, Stavroyianni N, Athanasiadou I, Chiotoglou I, Hadzidimitriou A, Athanasiadou A, Douka V, Saloum R, Laoutaris N, Anagnostopoulos A, Fassas A, Stathakis N, Kollia P (2006) Transferrin receptor-1 and 2 expression in chronic lymphocytic leukemia. Leuk Res 30:183–189CrossRefPubMedGoogle Scholar
  45. 45.
    Qing Y, Shuo W, Zhihua W, Huifen Z, Ping L, Lijiang L, Xiaorong Z, Liming C, Daiwen X, Yu H, Wei X, Min F, Zuohua F, Guanxin S (2006) The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor. Cancer Immunol Immunother CII 55:1111–1121CrossRefPubMedGoogle Scholar
  46. 46.
    Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY (1983) Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 36:539–545PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Brooks D, Taylor C, Dos Santos B, Linden H, Houghton A, Hecht TT, Kornfeld S, Taetle R (1995) Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. Clin Cancer Res Off J Am Assoc Cancer Res 1:1259–1265Google Scholar
  48. 48.
    Tros De Ilarduya C, Bunuales M, Qian C, Duzgunes N (2006) Antitumoral activity of transferrin-lipoplexes carrying the IL-12 gene in the treatment of colon cancer. J Drug Target 14:527–535CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Marc Cinci
    • 1
  • Srinivas Mamidi
    • 1
  • Wenhan Li
    • 1
  • Volker Fehring
    • 2
  • Michael Kirschfink
    • 1
  1. 1.Institute of ImmunologyUniversity of HeidelbergHeidelbergGermany
  2. 2.Silence Therapeutics AGBerlinGermany

Personalised recommendations